Independent Gateway to Understanding Type 2 Inflammation
Eosinophilic oesophagitis (EoE) is a chronic inflammatory disease requiring long-term therapeutic management [1-3]. Currently, swallowed topical corticosteroids (STC) are the first-line medical therapy for active disease [4]. Nonetheless, oesophageal targeting and efficacy of STC are suboptimal. A new formulation of budesonide orodispersible tablet (BOT) showed efficacy in EoE in a 6-week phase 3 trial [5]. The current phase 3, randomised,…
Rokkas T, et al. A network meta-analysis of randomized controlled trials on the treatment of eosinophilic esophagitis in adults and children. J Clin Gastroenterol 2020; published ahead of print. For eosinophilic esophagitis (EoE), apart from steroids [1], newer therapeutic interventions and relevant randomised controlled trials (RCTs) are available that have not been included in previous meta-analyses [2-6]. Network meta-analysis (NWM)…
Orodispersible budesonide delivered specifically to the oesophagus as a tablet was effective in inducing clinical and histological remission in patients with eosinophilic oesophagitis, according to the data from the EOS-2 trial, reported by Prof. Alfredo Lucendo (Tomelloso General Hospital, Spain) [1]. EOS-2 aimed to test the efficacy of a 6-week open-label induction treatment with oral budesonide (1 mg, twice daily)…